FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Immunomedics, Inc. patents


      
Recent patent applications related to Immunomedics, Inc.. Immunomedics, Inc. is listed as an Agent/Assignee. Note: Immunomedics, Inc. may have other listings under different names/spellings. We're not affiliated with Immunomedics, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics, Inc.-related inventors



Search recent Press Releases: Immunomedics, Inc.-related press releases
Count Application # Date Immunomedics, Inc. patents (updated weekly) - BOOKMARK this page
12014023420908/21/14Chimeric and humanized anti-histone antibodies
22014022717808/14/14Humanized anti-hla-dr antibodies
32014022717908/14/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
42014022718008/14/14Antibody-sn-38 immunoconjugates with a cl2a linker
52014022854108/14/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
62014021991408/07/14Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
72014021995608/07/14Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
82014021242507/31/14Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
92014019335907/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
102014017829406/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
112014017006506/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
122014015427306/05/14Anthracycline-antibody conjugates for cancer therapy
132014014738205/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
142014014092405/22/14Humanized l243 antibodies
152014014092405/22/14Humanized l243 antibodies
162014012003505/01/14Rs7 antibodies
172014012003505/01/14Rs7 antibodies
182014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
192014011286504/24/14Anti-cd19 antibodies
202014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
212014011286504/24/14Anti-cd19 antibodies
222014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
232014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
242014009925804/10/14Camptothecin-binding moiety conjugates
252014009925804/10/14Camptothecin-binding moiety conjugates
262014009925804/10/14Camptothecin-binding moiety conjugates
272014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
282014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
292014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
302014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
312014007962903/20/14Class i anti-cea antibodies and uses thereof
322014007962903/20/14Class i anti-cea antibodies and uses thereof
332014005806702/27/14Immunoconjugates with an intracellularly-cleavable linkage
342014004463902/13/14Antibody therapy
352014004464002/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
362014003754302/06/14Anti-pancreatic cancer antibodies
372014003826102/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
382014003828402/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
392014001716801/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
402014001719701/16/14Anti-cd19 antibodies
412014000407801/02/14Immunoconjugates with an intracellularly-cleavable linkage
422013031582111/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
432013030917711/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
442013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
452013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
462013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
472013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
482013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
492013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
502013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
512013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
522013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
532013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
542013017106407/04/13Anti-cd74 immunoconjugates and methods of use
552013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
562013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
572013017106407/04/13Anti-cd74 immunoconjugates and methods of use
582013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
592013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
602013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
612013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
622013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
632013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
642013015669106/20/13Antibody therapy
652013015669106/20/13Antibody therapy
662013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
672013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
682013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
692013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
702013012191305/16/13Anti-cd19 antibodies
712013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
722013012191305/16/13Anti-cd19 antibodies
732013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
742013009503404/18/13Anti-cd74 immunoconjugates and methods
752013009045804/11/13Immunoconjugates with an intracellularly-cleavable linkage
762013007818203/28/13Structural variants of antibodies for improved therapeutic characteristics
772013007826303/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
782013007132003/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
792013007140603/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
802013007265903/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
812013003986102/14/13Dye conjugated peptides for fluorescent imaging
822013003449202/07/13Class i anti-cea antibodies and uses thereof
832012032856412/27/12Camptothecin-binding moiety conjugates
842012032863412/27/12Immunoconjugates with an intracellularly-cleavable linkage
852012032155312/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
862012028217811/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
872012027610011/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
882012023095309/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
892012021496908/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
902012019632608/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
912012018954207/26/12Anti-cd19 antibodies
922012018347207/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
932012018355007/19/12Therapeutic using a bispecific antibody
942012014908506/14/12Fusion proteins containing recombinant cytotoxic rnases
952012014137206/07/12Rs7 antibodies
962012014137506/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
972012013492005/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
982012011455605/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
992012010723505/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1002012008829904/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
1012012008261704/05/12Immunoconjugates with an intracellularly-cleavable linkage
1022012007672703/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1032012006399303/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
1042012003979702/16/12Antibody therapy
1052012004043102/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1062012003418502/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
1072011031153112/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
1082011030563112/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1092011030006612/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
1102011029351312/01/11Immunoconjugates with an intracellularly-cleavable linkage
1112011028691811/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
1122011028080111/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1132011027470411/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1142011025605310/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1152011024384110/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
1162011024454610/06/11Internalizing anti-cd74 antibodies and methods of use
1172011023630409/29/11Structural variants of antibodies for improved therapeutic characteristics
1182011023640409/29/11Methods for protein expression in mammalian cells in serum-free medium
1192011022940709/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1202011022364509/15/11Multivalent carriers of bi-specific antibodies
1212011019502308/11/11Internalizing anti-cd74 antibodies and methods of use
1222011018908508/04/11Antibody therapy
1232011018926808/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1242011017112607/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1252011016507207/07/11Detection of early-stage pancreatic adenocarcinoma
1262011016507307/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1272011011701005/19/11Methods and compositions for administering therapeutic and diagnostic agents
1282011011710505/19/11Method of treating immune disease using b-cell antibodies
1292011011085405/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1302011007623303/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1312011007015503/24/11Anti-cd74 immunoconjugates and methods
1322011007015603/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1332011006465303/17/11Class i anti-cea antibodies and uses thereof
1342011005248903/03/11Anti-cd19 antibodies
1352010031116212/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
1362010028490611/11/10Internalizing anti-cd74 antibodies and methods of use
1372010027263610/28/10Anti-cd74 immunoconjugates and methods of use
1382010026649610/21/10Anti-cd74 immunoconjugates and methods of use
1392010026649710/21/10Internalizing anti-cd74 antibodies and methods of use
1402010023377909/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1412010022688409/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1422010022117509/02/10Antibody therapy
1432010022117709/02/10Rs7 antibodies
1442010021666208/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1452010020296108/12/10D-amino acid peptides
1462010019626608/05/10Humanized anti-hla-dr antibodies
1472010019626708/05/10Humanized l243 antibodies
1482010019698908/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1492010018964107/29/10Novel strategies for improved cancer vaccines
1502010015880206/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
1512010015880306/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1522010013662606/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1532010010458904/29/10Immunoconjugates with an intracellularly-cleavable linkage
1542010007484003/25/10Anthracycline-antibody conjugates for cancer therapy
1552010006813603/18/10Anti-cd19 antibodies
1562010004054102/18/10Structural variants of antibodies for improved therapeutic characteristics
1572010003473802/11/10Structural variants of antibodies for improved therapeutic characteristics
1582010001504601/21/10Camptothecin-binding moiety conjugates
1592010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1602010000885501/14/10Production and use of novel peptide-based agents with bispecific antibodies
1612010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1622009030458012/10/09Anti-pancreatic cancer antibodies
1632009029903312/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1642009029109311/26/09Immunoconjugates with an intracellularly-cleavable linkage
1652009028575211/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1662009027464911/05/09Bispecific antibody point mutations for enhancing rate of clearance
1672009025273110/08/09Multivalent carriers of bi-specific antibodies
1682009025317910/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
1692009024613010/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1702009024613110/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
1712009024621410/01/09Fusion proteins containing recombinant cytotoxic rnases
1722009023875709/24/09Methods and compositions for administering therapeutic and diagnostic agents
1732009024003709/24/09Humanized antibodies and methods of humanizing antibodies
1742009018597407/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1752009015516606/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1762009015525306/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
1772009011114304/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1782009009259804/09/09Antibody therapy
1792010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1802010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo